Compositions comprising bacterial strains

Abstract

The invention provides compositions comprising bacterial strains for treating and preventing cancer.

1 .- 30 . (canceled) 
     
     
         31 . A method of treating a non-immunogenic cancer in a subject in need thereof, comprising administering to the subject a pharmaceutical composition that comprises a bacterial strain of the species  Enterococcus gallinarum  comprising a plasmid with at least 93% sequence identity to the sequence of SEQ ID NO: 4, wherein said administering is sufficient to treat the non-immunogenic cancer. 
     
     
         32 . The method of  claim 31 , wherein said non-immunogenic cancer is a lung cancer. 
     
     
         33 . The method of  claim 32 , wherein said lung cancer is non-small-cell lung carcinoma or small-cell lung carcinoma. 
     
     
         34 . The method of  claim 31 , wherein said non-immunogenic cancer is a breast cancer. 
     
     
         35 . The method of  claim 34 , wherein said breast cancer is mammary carcinoma or stage IV breast cancer. 
     
     
         36 . The method of  claim 31 , wherein said non-immunogenic cancer is a liver cancer. 
     
     
         37 . The method of  claim 36 , wherein said liver cancer is hepatocellular carcinoma. 
     
     
         38 . The method of  claim 31 , wherein said non-immunogenic cancer is a colon cancer. 
     
     
         39 . The method of  claim 38 , wherein said colon cancer is colorectal adenocarcinoma. 
     
     
         40 . The method of  claim 31 , wherein said pharmaceutical composition comprises from about 1×10 6  to about 1×10 11  colony forming units (CFU) of said bacterial strain. 
     
     
         41 . The method of  claim 31 , wherein said pharmaceutical composition comprises from about 1×10 6  to about 1×10 11  colony forming units per gram (CFU/g) of said bacterial strain with respect to a total weight of said pharmaceutical composition. 
     
     
         42 . The method of  claim 31 , wherein said subject is human. 
     
     
         43 . The method of  claim 31 , wherein said a bacterial strain comprises a plasmid with at least 95% sequence identity to the sequence of SEQ ID NO: 4. 
     
     
         44 . The method of  claim 31 , wherein said a bacterial strain comprises a plasmid with at least 98% sequence identity to the sequence of SEQ ID NO: 4 
     
     
         45 . The method of  claim 31 , wherein said a bacterial strain comprises a plasmid with at least 99% sequence identity to the sequence of SEQ ID NO: 4. 
     
     
         46 . The method of  claim 31 , wherein said a bacterial strain is the  Enterococcus gallinarum  strain deposited under accession number NCIMB 42488, a derivative thereof, or a biotype thereof. 
     
     
         47 . The method of  claim 46 , wherein said biotype comprises a bacterial strain that has the carbohydrate fermentation profile as the bacterial strain deposited under accession number NCIMB 42488. 
     
     
         48 . The method of  claim 47 , wherein said carbohydrate fermentation profile comprises: (i) a positive fermentation of at least one of: L-arabinose and D-xylose; and (ii) an intermediate fermentation of Methyl-αD-glycopyranoside. 
     
     
         49 . The method of  claim 31 , wherein said pharmaceutical composition comprises only de minimis or biologically irrelevant amounts of other bacterial strains. 
     
     
         50 . The method of  claim 31 , wherein said pharmaceutical composition comprises the bacterial strain as part of a microbial consortium.